BACKGROUND: Regular screening of cirrhotic patients for hepatocellular carcinoma (HCC) has been suboptimal, but there is little data regarding specific risk factors for reduced screening. METHODS: From 1996 to 2010, patients with cirrhosis were retrospectively identified from outpatient gastroenterology and primary care practices. Data was obtained from the diagnosis of cirrhosis until the time of elevated alpha-fetoprotein (AFP) or lesion suspicious for HCC, death, liver transplantation, or end of the data collection period. Recommended screening was defined as abdominal imaging (ultrasound, contrast-enhanced CT, or MRI) with or without serum alpha-fetoprotein (AFP) at least once every 12 months based on professional guidelines. RESULTS: One hundred fifty-six patients with cirrhosis were identified. The etiologies of cirrhosis were viral hepatitis (n = 65), alcohol (n = 40), non-alcoholic steatohepatitis (NASH) (n = 27), and non-viral, non-alcoholic, non-NASH cirrhosis (n = 24). Of the 156 patients, 51% received recommended screening for HCC. Patients with NASH cirrhosis received recommended screening significantly less (p = 0.016) than cirrhotics with viral hepatitis, alcoholic cirrhosis, or non-viral, non-alcoholic, non-NASH cirrhosis and were less likely to receive gastroenterology referral (p < 0.001). Additionally, 20 patients were diagnosed with cirrhosis incidentally during a surgical procedure. These patients were significantly less likely to receive recommended HCC screening than those diagnosed non-surgically (10.0 vs. 56.6%; p < 0.001). Screening was significantly more likely to occur in patients seen regularly by a gastrointestinal subspecialist (66.7 vs. 22.8%; p < 0.001). CONCLUSIONS: Patients with NASH cirrhosis and incidentally discovered cirrhosis have low rates of HCC screening and are referred less often to gastroenterologists. These data suggest a need for increased education about NASH cirrhosis and better systems of communication among general practitioners, surgeons, and gastroenterologists.
BACKGROUND: Regular screening of cirrhotic patients for hepatocellular carcinoma (HCC) has been suboptimal, but there is little data regarding specific risk factors for reduced screening. METHODS: From 1996 to 2010, patients with cirrhosis were retrospectively identified from outpatient gastroenterology and primary care practices. Data was obtained from the diagnosis of cirrhosis until the time of elevated alpha-fetoprotein (AFP) or lesion suspicious for HCC, death, liver transplantation, or end of the data collection period. Recommended screening was defined as abdominal imaging (ultrasound, contrast-enhanced CT, or MRI) with or without serum alpha-fetoprotein (AFP) at least once every 12 months based on professional guidelines. RESULTS: One hundred fifty-six patients with cirrhosis were identified. The etiologies of cirrhosis were viral hepatitis (n = 65), alcohol (n = 40), non-alcoholic steatohepatitis (NASH) (n = 27), and non-viral, non-alcoholic, non-NASH cirrhosis (n = 24). Of the 156 patients, 51% received recommended screening for HCC. Patients with NASH cirrhosis received recommended screening significantly less (p = 0.016) than cirrhotics with viral hepatitis, alcoholic cirrhosis, or non-viral, non-alcoholic, non-NASH cirrhosis and were less likely to receive gastroenterology referral (p < 0.001). Additionally, 20 patients were diagnosed with cirrhosis incidentally during a surgical procedure. These patients were significantly less likely to receive recommended HCC screening than those diagnosed non-surgically (10.0 vs. 56.6%; p < 0.001). Screening was significantly more likely to occur in patients seen regularly by a gastrointestinal subspecialist (66.7 vs. 22.8%; p < 0.001). CONCLUSIONS:Patients with NASH cirrhosis and incidentally discovered cirrhosis have low rates of HCC screening and are referred less often to gastroenterologists. These data suggest a need for increased education about NASH cirrhosis and better systems of communication among general practitioners, surgeons, and gastroenterologists.
Authors: Daniel A Leffler; Naama Neeman; James M Rabb; Jacob Y Shin; Bruce E Landon; Kumar Pallav; Z Myron Falchuk; Mark D Aronson Journal: Gastroenterology Date: 2011-01-13 Impact factor: 22.682
Authors: F Degos; C Christidis; N Ganne-Carrie; J P Farmachidi; C Degott; C Guettier; J C Trinchet; M Beaugrand; S Chevret Journal: Gut Date: 2000-07 Impact factor: 23.059
Authors: Jorge A Marrero; Robert J Fontana; Grace L Su; Hari S Conjeevaram; Dawn M Emick; Anna S Lok Journal: Hepatology Date: 2002-12 Impact factor: 17.425
Authors: Yolanda Rodriguez Villalvazo; Jennifer S McDanel; Lauren A Beste; Antonio J Sanchez; Mary Vaughan-Sarrazin; David A Katz Journal: Health Serv Res Date: 2019-11-25 Impact factor: 3.402
Authors: Winston E Abara; P Spradling; Y Zhong; A Moorman; E H Teshale; L Rupp; S C Gordon; M Schmidt; J A Boscarino; Y G Daida; S D Holmberg Journal: J Gastrointest Cancer Date: 2020-06
Authors: Waled Mohsen; Marcia Rodov; Emilia Prakoso; Barbara Charlton; David G Bowen; David J Koorey; Nicholas A Shackel; Geoffrey W McCaughan; Simone I Strasser Journal: World J Gastroenterol Date: 2017-04-21 Impact factor: 5.742